Presence of CAT genetic markers as an indicator of accelerated rate of liver fibrosis progression in patients with chronic hepatitis
https://doi.org/10.31146/1682-8658-ecg-189-5-39-43
Abstract
Goal. To evaluate the genetic profi le of patients with chronic hepatitis C (CHC) by the CAT gene polymorphism in the region-262G/A (rs1001179), GPX4 in the region-718C/T (rs713041), IL28B in the region C/T (rs12979860) and VEGFA in the region- 634G/C (rs2010963) to analyze the association of the rate of progression of liver fi brosis with polymorphic genetic markers.
Materials and methods. We examined 36 patients with CHC with a rapidly progressive rate of fi brosis (up to 10 years) and 56 patients with a slowly progressive course of the disease (more than 10 years). The study of single- nucleotide polymorphisms of genes was carried out by the method of polymerase chain reaction.
Results. In the group with rapid progression of liver fi brosis, individuals with multiple risk alleles for the studied polymorphisms were more common, which confi rms the association of the risk of liver fi brosis progression with the genetic markers CAT in the region-262G/A (rs1001179) and GPX4 in the region-718C/T (rs713041) with their combined carrier. Among patients with rapid progression of fi brosis, a greater number of individuals had simultaneously 4–6 risk alleles in 27.5%, while patients with slow progression of the process only in 11% of cases.
Conclusion. This set of genetic markers can be used as genetic testing of patients with liver fibrosis to determine the prognosis of the disease.
About the Authors
I. A. Bulatova
University E. A. Wagner Perm State Medical University of the Ministry of Health of the Russian Federation
Russian Federation
Russian Federation
Irina A. Bulatova, Doctor of Medical Sciences, Head of the Department of Normal Physiology, Professor of the Department of Faculty Therapy No. 2, Occupational Pathology and Clinical Laboratory Diagnostics
26 Petropavlovsk str., Perm, 614990, Russia
T. P. Shevlyukova
Tyumen State Medical University of the Ministry of Health of the Russian Federation
Russian Federation
Russian Federation
Tatyana P. Shevlyukova, Doctor of Medical Sciences, Professor of the Department of Obstetrics and Gynecology
54 Odesskaya str., Tyumen, 625023, Russia
A. P. Shchekotova
University E. A. Wagner Perm State Medical University of the Ministry of Health of the Russian Federation
Russian Federation
Russian Federation
Alevtina P. Shchekotova, Doctor of Medical Sciences, Professor of the Department of Faculty Therapy No. 2, Occupational Pathology and Clinical Laboratory Diagnostics
26 Petropavlovsk str., Perm, 614990, Russia
A. V. Krivtsov
Federal Research Center for Medical and Preventive Technologies of Public Health Risk Management
Russian Federation
Russian Federation
Alexander V. Krivtsov, Candidate of Medical Sciences, Head of the Laboratory of Immunogenetics
82 Monastyrskaya str., Perm, 614045, Russia
References
1. Tsimmerman Ya. S. Liver fi brosis: pathogenesis, diagnostic methods, treatment prospects. Clin. Pharmacol. Ther., 2017;26 (1):54–58. (in Russian)
2. Ivashkin, V. T. Liver fi brosis. Moscow. GEOTAR-Media, 2011, 168 P. (in Russian)
3. Pinzani M, Romanelli R, Magli S. Progression of fibrosis in chronic liver diseases: time to tall the score. J Hepatol. 2001;34:764–7.
4. Kurysheva M. A. Liver fi brosis: past, present, and future. RMZ. 2010; 18(28):1713–16. (in Russian)
5. Mekhtiev S. N., Stepanenko V. V., Zinov’eva E.N., Mekhtieva O. A. Modern ideas about liver fibrosis and methods of its correction. Farmateka. 2014, No. 6, pp. 80–87. (in Russian)
6. Pavlov Ch. S., Zolotarevskiy V. B., Tomkevich M. S., et al. The possibility of reversibility of cirrhosis of the liver (clinical and pathogenetic prerequisites). Rossiyskiy zhurnal gastroenterologii, gepatologii, koloproktologii. 2006; 16(1):20–29. (in Russian)
7. Ellis E. L., Mann D. A. Clinical evidence for the regression of liver fibrosis. J. Hepatol. 2012;56(5):1171–1180.
8. Ivashkin V. T., Yushchuk N. D., Maevskaya M. V. Recommendations for the diagnosis and treatment of adult patients with hepatitis C. Rossiyskiy zhurnal gastroenterologii, gepatologii, koloproktologii. 2013;23(2): 41–70. (in Russian)
9. Krasnova L.I., Nikol’skaya M. V. The incidence and severity of liver fibrosis in patients with chronic viral hepatitis, depending on the age and duration of the disease. Collection of abstracts of the 19th Russian Congress “Hepatology Today”. 2014. 26 P. (in Russian)
10. Bartenschlager R., Lohmann, V., Penin F. The molecular and structural basis of advanced antiviral therapy for hepatitis C virus infection. Nat. Rev. Microbiol. 2013, No. 11, pp. 482–496.
11. Wynn А. Cellular and molecular mechanisms of fi brosis. J. Pathol. 2008, No. 214, pp. 199–210.
12. Geyvandova N. I., Yagoda A. V., Gudzovskaya D. A., Kostornaya I. V. Serum phospholipids, indicators of lipid peroxidation and antioxidant protection as additional non-invasive markers of the activity of chronic viral hepatitis C. Rossiyskiy zhurnal gastroenterologii, gepatologii i koloproktologii. 2008;(18):38–42. (in Russian)
13. Parola M., Robino G. Oxidative stress- related molecules and liver fi brosis. J. Hepatol. 2001. Vol. 35, pp. 297–306.
14. Bataller R., Brenner D. A. Liver fi brosis. J. Clin. Invest. 2005;2 (115):209–218.
15. Rauch A., Kutalik Z., Descombes Р. et al. Genetic variation in IL28 B is associated with chronic hepatitis C and treatment failure: a genome-wide association study. Gastroenterology. 2010;138(4):1338–1345.
16. Ermolova T.V., Ermolov S. Yu., Sologub T. V., Karev V. E., Dobkes A. L. Some mechanisms of intrahepatic hemodynamic disorders and its correction in chronic liver diseases with an initial stage of fibrosis. Experimental and Clinical Gastroenterology. 2018;(2):183–191. (In Russ.)
17. Taratina O. V., Krasnova T. N., Samokhodskaya L. M., et al. Polymorphism of endothelial dysfunction genes and the rate of progression of liver fibrosis in chronic hepatitis C. Terapevticheskiy arkhiv. 2014;86(4):45–51. (in Russian)
18. Shchekotova A.P., Bulatova I. A. The role of vasculoendothelial growth factor and its gene in the pathogenesis of hepatobiliary pathology. Permskiy meditsinskiy zhurnal. 2020;37(4):36–45. DOI: 10.17816/pmj37436–45 (in Russian)
Review
For citations:
Bulatova I.A., Shevlyukova T.P., Shchekotova A.P., Krivtsov A.V. Presence of CAT genetic markers as an indicator of accelerated rate of liver fibrosis progression in patients with chronic hepatitis. Experimental and Clinical Gastroenterology. 2021;1(5):39-43. (In Russ.) https://doi.org/10.31146/1682-8658-ecg-189-5-39-43
Views:
469
Email this article 